Theralink® Technologies Achieves California CLIA Clinical and Public Health Certification

Denver, Colorado – March 29th, 2021 – Theralink Technologies, Inc. (OTC: OBMP), a
precision medicine and molecular profiling company specializing in patented, biomarker
assay services that target multiple areas of oncology, today announced that the Company
has received Clinical and Public Health License from the State of California for its Golden,
Colorado laboratory, effective March 11th, 2021.

The CLIA program is put in place by the Centers for Medicare & Medicaid Services (CMS)
to regulate laboratories that test human specimens. The results of the California CLIA
License allow Theralink to accept and perform testing on human specimens from
California. The California Clinical and Public Health License survey showed that all CLIA
Condition-level requirements were met, adhering to the highest standards in the industry.

“We are thrilled to receive the California Clinical and Public Health License for our Golden,
CO laboratory as this was truly a team effort. Receiving the California licensure is a key
step in our growth strategy as we plan to expand our testing capabilities and uncover key
insights that may improve cancer treatment for breast cancer patients,” said Mick Ruxin,
M.D., President & CEO of Theralink Technologies, Inc. “With the Clinical and Public
Health License from the State of California, we expect to begin receiving, testing and
billing for patient’s breast cancer tumor specimens in California in Q2 2021.”

About Theralink Technologies, Inc.
Theralink Technologies is a proteomics-based, molecular profiling and precision medicine
company with a CLIA-certified laboratory located in Golden, Colorado. Through its unique
and patented phosphoprotein and protein biomarker platform and LDTs, Theralink’s
technology targets multiple areas of oncology and drug development. Theralink provides
precision oncology data through its powerful Theralink® Reverse Phase Protein Array
assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely
responders and non-responders to both FDA-approved and investigational drug
treatments. Theralink intends to help improve cancer outcomes for patients, help reveal
therapeutic options for oncologists, and support biopharmaceutical drug development by
using a beyond-genomics approach to molecular profiling that directly measures drug
target levels and activity. For more information, please visit

Contact Information
The Firm Public Relations & Marketing
Jasen Woehrle and Jesse Scott
2 June 13, 2020

Forward-Looking Statements
Certain statements contained in this press release are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act of 1995, including,
without limitation, anything relating or referring to future financial results, patient
enrollment and plans for future business development activities, and are thus prospective.
Forward-looking statements are inherently subject to risks and uncertainties some of
which cannot be predicted or quantified based on current expectations. Such risks and
uncertainties include, without limitation, the risks and uncertainties set forth from time to
time in reports filed by Theralink Technologies with the Securities and Exchange
Commission. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends affecting the
financial condition of our business and although the company believes that the
expectations reflected in such forward-looking statements are reasonable, it can give no
assurance that such expectations will prove to have been correct. Consequently, future
events and actual results could differ materially from those set forth in, contemplated by,
or underlying the forward the forward-looking statements contained herein. The company
undertakes no obligation to publicly release statements made to reflect events or
circumstances after the date hereof.